hrcak mascot   Srce   HID

Izvorni znanstveni članak

Sentimag sentinel lymph node biopsy in breast conservative surgery – preliminary results

Ilija Guteša ; Department of Surgical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ivana Potesak ; Department of Surgical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ivana Pavičić ; Department of Surgical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Gordan Tometić ; Department of Surgical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Iva Kirac ; Department of Surgical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ivan Penavić ; Department of Surgical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ivan Milas ; Department of Surgical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Mladen Stanec ; Department of Surgical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

Puni tekst: engleski, pdf (262 KB) str. 15-19 preuzimanja: 227* citiraj
APA 6th Edition
Guteša, I., Potesak, I., Pavičić, I., Tometić, G., Kirac, I., Penavić, I., ... Stanec, M. (2016). Sentimag sentinel lymph node biopsy in breast conservative surgery – preliminary results. Libri Oncologici, 44 (2-3), 15-19. Preuzeto s https://hrcak.srce.hr/177104
MLA 8th Edition
Guteša, Ilija, et al. "Sentimag sentinel lymph node biopsy in breast conservative surgery – preliminary results." Libri Oncologici, vol. 44, br. 2-3, 2016, str. 15-19. https://hrcak.srce.hr/177104. Citirano 13.05.2021.
Chicago 17th Edition
Guteša, Ilija, Ivana Potesak, Ivana Pavičić, Gordan Tometić, Iva Kirac, Ivan Penavić, Ivan Milas i Mladen Stanec. "Sentimag sentinel lymph node biopsy in breast conservative surgery – preliminary results." Libri Oncologici 44, br. 2-3 (2016): 15-19. https://hrcak.srce.hr/177104
Harvard
Guteša, I., et al. (2016). 'Sentimag sentinel lymph node biopsy in breast conservative surgery – preliminary results', Libri Oncologici, 44(2-3), str. 15-19. Preuzeto s: https://hrcak.srce.hr/177104 (Datum pristupa: 13.05.2021.)
Vancouver
Guteša I, Potesak I, Pavičić I, Tometić G, Kirac I, Penavić I i sur. Sentimag sentinel lymph node biopsy in breast conservative surgery – preliminary results. Libri Oncologici [Internet]. 2016 [pristupljeno 13.05.2021.];44(2-3):15-19. Dostupno na: https://hrcak.srce.hr/177104
IEEE
I. Guteša, et al., "Sentimag sentinel lymph node biopsy in breast conservative surgery – preliminary results", Libri Oncologici, vol.44, br. 2-3, str. 15-19, 2016. [Online]. Dostupno na: https://hrcak.srce.hr/177104. [Citirano: 13.05.2021.]

Sažetak
Segmentectomy and sentinel lymph node biopsy is a golden standard for early breast cancer (clinical and radiological cT1-2, c N0). Recently, superparamagnetic iron oxide (SPIO) nanoparticle tracer has been introduced enabling intraoperative tracer injection. We prospectively recorded data on tumor histology, marked lymph nodes and their final histology and patient characteristics for early breast cancer patients who underwent breast conservative surgery. At 128 female breast cancer patients underwent sentinel lymph node biopsy by SentiMag. Three patients were excluded from further analysis
because the postoperative pathology report was ductal carcinoma in situ (DCIS). The identifi cation rate was 95.2 % (119 of 125). Of the 19.2 % (24 of 125) patients with lymph node involvement, 1.6% (2 of 125) had micrometastasis, and 1 % (1 of 125) had single tumor cells within the sentinel, l at least a micrometastasis. Of 30 positive lymph nodes removed, 24 (80 %) were true sentinel nodes. The average lymph node retrieval rate was 2.3 nodes per patient. SentiMag’s performance was comparable to published data and to standard sentinel with blue patent die and/or technetium. The benefi t of easier application and logistics is a great advantage.

Ključne riječi
SentiMag; Sienna+®; superparamagnetic iron oxide; early breast cancer

Hrčak ID: 177104

URI
https://hrcak.srce.hr/177104

[hrvatski]

Posjeta: 539 *